These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 32987821)

  • 1. Ceftolozane/Tazobactam and Ceftazidime/Avibactam for Multidrug-Resistant Gram-Negative Infections in Immunocompetent Patients: A Single-Center Retrospective Study.
    Cultrera R; Libanore M; Barozzi A; d'Anchera E; Romanini L; Fabbian F; De Motoli F; Quarta B; Stefanati A; Bolognesi N; Gabutti G
    Antibiotics (Basel); 2020 Sep; 9(10):. PubMed ID: 32987821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
    Weber C; Schultze T; Göttig S; Kessel J; Schröder A; Tietgen M; Besier S; Burbach T; Häussler S; Wichelhaus TA; Hack D; Kempf VAJ; Hogardt M
    Microbiol Spectr; 2022 Oct; 10(5):e0169722. PubMed ID: 36190424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences.
    Criscuolo M; Trecarichi EM
    Antibiotics (Basel); 2020 Feb; 9(2):. PubMed ID: 32028615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Infections Due to MDR Gram-Negative Bacteria.
    Bassetti M; Peghin M; Vena A; Giacobbe DR
    Front Med (Lausanne); 2019; 6():74. PubMed ID: 31041313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.
    van Duin D; Bonomo RA
    Clin Infect Dis; 2016 Jul; 63(2):234-41. PubMed ID: 27098166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant
    Vena A; Giacobbe DR; Castaldo N; Cattelan A; Mussini C; Luzzati R; Rosa FG; Del Puente F; Mastroianni CM; Cascio A; Carbonara S; Capone A; Boni S; Sepulcri C; Meschiari M; Raumer F; Oliva A; Corcione S; Bassetti M
    Antibiotics (Basel); 2020 Feb; 9(2):. PubMed ID: 32050434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).
    Sader HS; Flamm RK; Carvalhaes CG; Castanheira M
    Diagn Microbiol Infect Dis; 2020 Mar; 96(3):114833. PubMed ID: 31924426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of
    Sid Ahmed MA; Khan FA; Hadi HA; Skariah S; Sultan AA; Salam A; Al Khal AL; Söderquist B; Ibrahim EB; Omrani AS; Jass J
    Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of intensive care unit patients infected with multidrug-resistant gram-negative bacteria treated with ceftazidime/avibactam and ceftolozane/tazobactam.
    Neves CS; Moura LCRV; Da Costa Lima JL; Maciel MAV
    Braz J Microbiol; 2024 Mar; 55(1):333-341. PubMed ID: 38133795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Shields RK; Clancy CJ; Pasculle AW; Press EG; Haidar G; Hao B; Chen L; Kreiswirth BN; Nguyen MH
    J Clin Microbiol; 2018 Feb; 56(2):. PubMed ID: 29167294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant Gram-negative organisms: A real-life experience.
    Meschiari M; Faltoni M; Kaleci S; Tassoni G; Orlando G; Franceschini E; Burastero G; Bedini A; Serio L; Biagioni E; Melegari G; Venturelli C; Sarti M; Bertellini E; Girardis M; Mussini C
    Int J Antimicrob Agents; 2024 May; 63(5):107134. PubMed ID: 38453094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
    Clerici D; Oltolini C; Greco R; Ripa M; Giglio F; Mastaglio S; Lorentino F; Pavesi F; Farina F; Liberatore C; Castiglion B; Tassan Din C; Bernardi M; Corti C; Peccatori J; Scarpellini P; Ciceri F; Castagna A
    Int J Antimicrob Agents; 2021 Jun; 57(6):106335. PubMed ID: 33838223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.
    Zhen S; Wang H; Feng S
    Infection; 2022 Dec; 50(6):1409-1423. PubMed ID: 35781869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by
    Daikos GL; da Cunha CA; Rossolini GM; Stone GG; Baillon-Plot N; Tawadrous M; Irani P
    Antibiotics (Basel); 2021 Sep; 10(9):. PubMed ID: 34572708
    [No Abstract]   [Full Text] [Related]  

  • 17.
    Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
    Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
    Sid Ahmed MA; Abdel Hadi H; Hassan AAI; Abu Jarir S; Al-Maslamani MA; Eltai NO; Dousa KM; Hujer AM; Sultan AA; Soderquist B; Bonomo RA; Ibrahim EB; Jass J; Omrani AS
    J Antimicrob Chemother; 2019 Dec; 74(12):3497-3504. PubMed ID: 31504587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
    Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D
    Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.